ampelopsin has been researched along with Atherogenesis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, S; Jin, R; Li, X; Tan, L; Tong, H; Zhang, X | 1 |
| Chen, L; Deng, X; Deng, Y; He, G; He, J; Jiang, P; Kuang, D; Li, J; Li, R; Luo, J; Luo, S; Tan, S; Yan, M; Yang, D; Yang, Z; Yuan, Q; Zhou, Y; Zou, Y | 1 |
| Chen, X; Liu, TT; Tang, K; Xu, XL; Zeng, Y; Zhang, W | 1 |
| Dong, X; Lu, S; Luo, Y; Sun, G; Sun, X; Xu, L | 1 |
| Peng, Y; Tang, K; Wang, YQ; Wei, XY; Xu, XL; Zeng, Y; Zhao, ZY | 1 |
1 review(s) available for ampelopsin and Atherogenesis
| Article | Year |
|---|---|
Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases.
Topics: Animals; Atherosclerosis; Diabetes Mellitus; Flavonols; Gene Expression Regulation; Humans; Hypoglycemic Agents; Metabolic Diseases; Non-alcoholic Fatty Liver Disease; Osteoporosis; Signal Transduction | 2020 |
4 other study(ies) available for ampelopsin and Atherogenesis
| Article | Year |
|---|---|
Dihydromyricetin increases endothelial nitric oxide production and inhibits atherosclerosis through microRNA-21 in apolipoprotein E-deficient mice.
Topics: Amidohydrolases; Animals; Apolipoproteins E; Arginine; Atherosclerosis; Enzyme Activation; Flavonols; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Lipid Metabolism; Lipids; Liver; Male; Mice, Inbred C57BL; MicroRNAs; Nitric Oxide; Nitric Oxide Synthase Type III; Signal Transduction | 2020 |
Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta; Aortic Diseases; Atherosclerosis; Cytokines; Diet, High-Fat; Disease Models, Animal; Flavonols; Foam Cells; Genetic Predisposition to Disease; Human Umbilical Vein Endothelial Cells; Humans; Inflammation Mediators; Lipoproteins, LDL; Liver; Male; Mice; Mice, Knockout; Oxidative Stress; Phenotype; Plaque, Atherosclerotic; RAW 264.7 Cells; Receptors, LDL | 2017 |
Dihydromyricetin protects human umbilical vein endothelial cells from injury through ERK and Akt mediated Nrf2/HO-1 signaling pathway.
Topics: Apoptosis; Atherosclerosis; Cell Survival; Flavonols; Flow Cytometry; Heme Oxygenase-1; Human Umbilical Vein Endothelial Cells; Humans; MAP Kinase Signaling System; NF-E2-Related Factor 2; Oncogene Protein v-akt; Oxidative Stress; Protective Agents; Reactive Oxygen Species; Signal Transduction | 2017 |
Dihydromyricetin ameliorates foam cell formation via LXRα-ABCA1/ABCG1-dependent cholesterol efflux in macrophages.
Topics: Animals; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Cholesterol; Dose-Response Relationship, Drug; Flavonols; Foam Cells; Humans; Liver X Receptors; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; THP-1 Cells | 2018 |